Navigation Links
Cardiome Provides Regulatory Update


VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has been informed by its co-development partner, Astellas Pharma US, Inc., that an End of Review meeting with the U.S. Food & Drug Administration (FDA) has been scheduled for November 14th, 2008 regarding the New Drug Application (NDA) for KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. At the conclusion of FDA's review of an application and the issuance of an action letter, FDA provides applicants with an opportunity to meet with agency reviewing officials to discuss what further steps need to be taken by the applicant before the application can be approved.

Cardiome has also been informed by Astellas that, in an effort to align the North American regulatory strategy, Astellas has elected to withdraw the New Drug Submission (NDS) for KYNAPID with the Therapeutic Products Directorate (TPD) of Health Canada, originally submitted in May 2007. Cardiome and Astellas intend to revisit the Canadian regulatory strategy following resolution of the FDA process.

"Since receiving the FDA Approvable Letter in August, Cardiome and Astellas have been working diligently to collate information and analyses relevant to the issues raised in the action letter, and this meeting is intended to provide us with clear guidance so that we can focus our efforts on providing a robust response and attain U.S. approval for KYNAPID," said Bob Rieder, Chief Executive Officer of Cardiome. "We look forward to working with the FDA with the goal of having KYNAPID available to appropriate patients as soon as possible."

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at and the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiome To Release Second Quarter Results And Hold Conference Call
2. Cardiome Announces Preferred Share Financing
3. Cardiome Announces Positive Phase 2b Results For Oral Vernakalant
4. Cardiome To Hold Conference Call
5. Cardiome Reports First Quarter Results
6. Cardiome To Release 2008 First Quarter Results
7. Cardiome To Release 2007 Results
8. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
9. Cardiome And Astellas Announce Regulatory Update
10. Cardiome to Hold Investor Update Call
11. Cardiome Updates Guidance
Post Your Comments:
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... music star Jessie James Decker made a brave but slightly unusual choice to show ... quickly returning to her pre-pregnancy form may have been pre-mature. Saying that she didn’t ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... education course in Dallas, TX, on January 29 and 30, 2016. The course ... the functions of their practices, to learn how to better succeed in the ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of travel insurance ... Television’s Travel With Kids to promote family vacations around the world. The television ... international destinations and educate families about the people and places of the world, all ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... up by athletic teams looking to maximize recovery through quality sleep. Tim DiFrancesco, ... and consistently get a better night’s sleep. ChiliPad precisely regulates the surface temperature ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood sugar tests ... adults, according to a new study by researchers at the School of Public Health ... Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , November 30, 2015 /PRNewswire/ ... --> adds a ... for 2010 - 2015 with comprehensive ... a range of deal types, such ... strategic alliances. ...
(Date:11/30/2015)... Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing devices ... systems, and PTS Detect™ cotinine systems, has announced the ... the company into the mHealth market. ... The technology is a system that interfaces with mobile ... and uses test strip technology already developed by PTS ...
(Date:11/30/2015)... , Nov. 30, 2015 iCAD, Inc. ... will feature its latest solutions for advanced image ... of cancer at the Radiological Society of North ... Chicago from November 29 to December ... advances including iReveal®, an automated breast density assessment ...
Breaking Medicine Technology: